Anti-VEGF Agents Indian Medical PG Practice Questions and MCQs
Practice Indian Medical PG questions for Anti-VEGF Agents. These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
Anti-VEGF Agents Indian Medical PG Question 1: During angiogenesis, what factors are responsible for the recruitment of pericytes and periendothelial cells?
- A. VEGF & PDGF
- B. Angiopoietins, TGF & PDGF (Correct Answer)
- C. VEGF, IL-2, IL-6
- D. TGF, VEGF & PDGF
Anti-VEGF Agents Explanation: ***Angiopoietins, TGF & PDGF***
- **Angiopoietins** are crucial for the stabilization of blood vessels and recruitment of **pericytes**, enhancing vessel maturation [1].
- **TGF (Transforming Growth Factor)** and **PDGF (Platelet-Derived Growth Factor)** also play significant roles in the recruitment and proliferation of **pericytes** and periendothelial cells during angiogenesis [1].
*VEGF & PDGF*
- While **VEGF (Vascular Endothelial Growth Factor)** is important for endothelial cell migration and proliferation, it does not directly recruit **pericytes** alone.
- This combination lacks **angiopoietins**, which are key for the stabilization of newly formed blood vessels [1].
*VEGF, IL-2, IL-6*
- **IL-2** and **IL-6** are primarily associated with immune responses and do not directly contribute to pericyte recruitment during angiogenesis.
- **VEGF** alone supports endothelial cells but does not effectively recruit **pericytes** without the cooperation of other factors.
*TGF, VEGF & PDGF*
- Although both **TGF** and **PDGF** are involved in pericyte recruitment [1], the absence of **angiopoietins** limits the effectiveness of this combination for the recruitment process.
- **VEGF** alone does not facilitate direct recruitment of **pericytes**, as it mainly focuses on endothelial cells.
**References:**
[1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Inflammation and Repair, pp. 115-116.
Anti-VEGF Agents Indian Medical PG Question 2: In which of the following conditions does IOL implantation after cataract surgery require the greatest caution and specialized management?
- A. Fuchs' heterochromic iridocyclitis
- B. Psoriatic arthritis
- C. Reiter's syndrome
- D. Juvenile rheumatoid arthritis (Correct Answer)
Anti-VEGF Agents Explanation: ***Juvenile rheumatoid arthritis***
- Patients with **juvenile rheumatoid arthritis (JRA)**, particularly those with **pauciarticular JRA** and **ANA positivity**, are at high risk for developing chronic uveitis, which can lead to significant cataract formation and severe postoperative complications.
- Due to the high risk of severe postoperative inflammation, glaucoma, and vision loss, IOL implantation in JRA patients requires extensive preoperative optimization of inflammation and careful intraoperative/postoperative management.
*Fuchs' heterochromic iridocyclitis*
- This condition presents with chronic, low-grade, **non-granulomatous anterior uveitis** and often leads to cataract formation.
- While IOL implantation in these patients is generally well-tolerated, it does not pose the same high risk of severe postoperative inflammation and complications as seen in JRA-associated uveitis.
*Psoriatic arthritis*
- Psoriatic arthritis can be associated with acute anterior uveitis, but it typically presents as an acute, intermittent inflammation.
- The risk of chronic, severe uveitis leading to complex cataract surgery and significant postoperative complications is not as consistently high or as severe as in JRA.
*Reiter's syndrome*
- Reiter's syndrome (now part of **reactive arthritis**) is another seronegative spondyloarthropathy that can cause acute anterior uveitis.
- Similar to psoriatic arthritis, the uveitis is usually acute and self-limiting, and while ocular inflammation needs to be controlled, the risk profile for IOL implantation is not as challenging as in JRA.
Anti-VEGF Agents Indian Medical PG Question 3: In diabetic retinopathy, which layer of the retina is primarily affected?
- A. Layer of rods and cones
- B. Retinal pigment epithelium
- C. Outer plexiform layer
- D. Inner nuclear layer (Correct Answer)
Anti-VEGF Agents Explanation: ***Inner nuclear layer***
- The inner nuclear layer contains the **retinal capillary network**, which is the primary site of pathology in diabetic retinopathy.
- **Microangiopathy** (pericyte loss, basement membrane thickening, endothelial cell damage) occurs in the capillaries located within this layer.
- **Microaneurysms**, the earliest ophthalmoscopic sign of diabetic retinopathy, form from damaged capillaries in the inner nuclear layer.
- **Diabetic macular edema (DME)** involves fluid accumulation that begins at the level of the capillaries in the inner nuclear and inner plexiform layers, then extends to the outer plexiform layer.
*Outer plexiform layer*
- This layer is **secondarily affected** by leakage from damaged capillaries in deeper retinal layers (inner nuclear and inner plexiform layers).
- **Hard exudates** (lipid and protein deposits) accumulate in the outer plexiform layer as a consequence of capillary leakage, but this is not the primary site of vascular pathology.
- The outer plexiform layer itself has minimal vasculature and is not where the initial microvascular changes occur.
*Layer of rods and cones*
- Photoreceptors are affected only in advanced stages of diabetic retinopathy due to chronic ischemia and secondary damage.
- The primary pathology is vascular and occurs in the inner retinal layers where capillaries are located, not in the avascular photoreceptor layer.
*Retinal pigment epithelium*
- The RPE is not directly affected by the microvascular changes that characterize diabetic retinopathy.
- RPE dysfunction is more characteristic of **age-related macular degeneration (AMD)** and other degenerative conditions.
- In diabetic retinopathy, the RPE may be affected indirectly in very advanced cases but is not a primary site of pathology.
Anti-VEGF Agents Indian Medical PG Question 4: Which of the following drugs is approved for treatment of both relapsing-remitting AND primary progressive multiple sclerosis?
- A. Fingolimod
- B. Omalizumab
- C. Ocrelizumab (Correct Answer)
- D. Natalizumab
Anti-VEGF Agents Explanation: ***Ocrelizumab***
- This **anti-CD20 monoclonal antibody** is uniquely approved for both **relapsing-remitting MS (RRMS)** and **primary progressive MS (PPMS)**.
- It targets **CD20-expressing B cells**, providing comprehensive disease modification across different MS phenotypes.
*Fingolimod*
- This **sphingosine 1-phosphate receptor modulator** is approved only for **relapsing-remitting MS**, not primary progressive MS.
- While effective for RRMS, it lacks the **dual indication** that makes Ocrelizumab the most comprehensive treatment option.
*Omalizumab*
- This **anti-IgE monoclonal antibody** is used for **severe allergic asthma** and **chronic idiopathic urticaria**.
- It has **no role in multiple sclerosis treatment** and works through IgE-mediated allergic pathways unrelated to MS pathophysiology.
*Natalizumab*
- This **integrin receptor antagonist** is used for MS but is typically reserved as **second-line therapy** due to **PML risk**.
- Unlike Ocrelizumab, it is **not approved for primary progressive MS** and requires careful monitoring for serious complications.
Anti-VEGF Agents Indian Medical PG Question 5: Which of the following is the platinum-based chemotherapeutic agent used as first-line treatment for ovarian carcinoma?
- A. Cyclophosphamide
- B. Methotrexate
- C. Cisplatin (Correct Answer)
- D. Dacarbazine
Anti-VEGF Agents Explanation: ***Cisplatin***
- **Cisplatin** is a platinum-based chemotherapy drug that forms **DNA cross-links**, inhibiting DNA synthesis and leading to the death of rapidly dividing cells, making it highly effective against **ovarian carcinoma**.
- It is a cornerstone of chemotherapy regimens for ovarian cancer, often used in combination with other agents such as paclitaxel.
*Methotrexate*
- **Methotrexate** is an **antimetabolite** that inhibits dihydrofolate reductase, thereby interfering with DNA synthesis.
- While it is used in various cancers like leukemia, lymphoma, and some solid tumors (e.g., breast cancer, gestational trophoblastic disease), it is **not a primary recommended drug for ovarian carcinoma**.
*Cyclophosphamide*
- **Cyclophosphamide** is an **alkylating agent** that causes DNA damage, leading to cell death.
- It is used in many cancers, including lymphoma, breast cancer, and some leukemias, but it is **not a first-line or primary agent for ovarian carcinoma** in contemporary treatment guidelines.
*Dacarbazine*
- **Dacarbazine** is an **alkylating agent** primarily used in the treatment of **malignant melanoma** and Hodgkin lymphoma.
- It is **not indicated for the treatment of ovarian carcinoma**.
Anti-VEGF Agents Indian Medical PG Question 6: What is the mechanism of action of Bevacizumab?
- A. Anti VEGF antibody (Correct Answer)
- B. Histone deacetylase inhibitor
- C. HER2 neu inhibitor
- D. Proteasome inhibitor
Anti-VEGF Agents Explanation: ***Anti VEGF antibody***
- **Bevacizumab** is a **monoclonal antibody** that specifically targets and binds to vascular endothelial growth factor (VEGF).
- By inhibiting VEGF, bevacizumab prevents the formation of new blood vessels (**angiogenesis**) that tumors need to grow and metastasize.
*Histone deacetylase inhibitor*
- **Histone deacetylase (HDAC) inhibitors** influence gene expression by modifying chromatin structure, leading to cell cycle arrest and apoptosis in cancer cells.
- They are used in certain hematologic malignancies and solid tumors but do not directly interfere with angiogenesis.
*Proteasome inhibitor*
- **Proteasome inhibitors** like bortezomib block the action of proteasomes, leading to an accumulation of ubiquitinated proteins and induction of apoptosis in cancer cells.
- This mechanism is distinct from blocking new blood vessel formation.
*HER2 neu inhibitor*
- **HER2 neu inhibitors** (e.g., trastuzumab) specifically target the HER2/neu receptor, which is overexpressed in certain breast and gastric cancers.
- Their action primarily involves blocking growth signals transmitted through this receptor, not inhibiting VEGF or angiogenesis.
Anti-VEGF Agents Indian Medical PG Question 7: A 56 year old patient presents after 3 days of cataract surgery with a history of increasing pain and diminution of vision after an initial improvement. The most likely cause would be:
- A. Endophthalmitis (Correct Answer)
- B. Central retinal vein occlusion
- C. Posterior capsular opacification (PCO)
- D. Retinal detachment
Anti-VEGF Agents Explanation: ***Endophthalmitis***
- **Endophthalmitis** is a severe inflammation of the intraocular fluids (vitreous and aqueous humor), most commonly caused by infection following cataract surgery.
- The presentation of **increasing pain** and **diminution of vision** a few days after initial improvement is a classic sign of acute post-operative endophthalmitis.
*Central retinal vein occlusion*
- **Central retinal vein occlusion (CRVO)** typically causes sudden, painless vision loss.
- It is not commonly associated with **increasing pain** or a temporal relationship to recent cataract surgery in this manner.
*Posterior capsular opacification (PCO)*
- **Posterior capsular opacification (PCO)** develops weeks or months after cataract surgery, not within a few days.
- It presents as gradual, painless blurring of vision without significant pain.
*Retinal detachment*
- **Retinal detachment** typically presents with sudden vision loss, flashes of light (photopsia), and floaters.
- While it can occur after cataract surgery, it is less likely to present with **increasing pain** as the primary symptom described.
Anti-VEGF Agents Indian Medical PG Question 8: Which of the following DPP-IV inhibitors is safe for use in chronic kidney disease patients without requiring dose modification?
- A. Sitagliptin
- B. Vildagliptin
- C. Linagliptin (Correct Answer)
- D. Saxagliptin
Anti-VEGF Agents Explanation: ***Linagliptin***
- Unlike other **DPP-IV inhibitors**, **linagliptin** is primarily eliminated via **biliary/fecal excretion** (~85%) rather than renal excretion.
- This unique elimination pathway makes it **safe** for use in patients with **chronic kidney disease** at its usual dose, without the need for dose adjustment.
- It is the **only DPP-IV inhibitor** that does not require dose modification in CKD.
*Sitagliptin*
- **Sitagliptin** is primarily eliminated by the **kidneys** (~80% renal excretion), requiring **significant dose adjustments** in patients with **renal impairment**.
- Without dose modification, there is an increased risk of **drug accumulation** and adverse effects in CKD patients.
*Vildagliptin*
- **Vildagliptin** undergoes **hydrolysis** with subsequent **renal excretion** of inactive metabolites, requiring **dose reduction** in patients with moderate to severe **renal impairment**.
- Not recommended in severe renal impairment (eGFR <50 mL/min).
*Saxagliptin*
- **Saxagliptin** is partially eliminated via **renal excretion** and requires **dose reduction** by 50% in patients with moderate to severe **CKD**.
- Both parent drug and active metabolite accumulate in renal impairment, necessitating dose adjustment.
Anti-VEGF Agents Indian Medical PG Question 9: In which of the following clinical conditions does the use of anticoagulants provide maximum benefit?
- A. Prevention of recurrences of myocardial infarction
- B. Prevention of venous thrombosis and pulmonary embolism (Correct Answer)
- C. Prevention of cerebrovascular accident (stroke)
- D. Retinal artery thrombosis
Anti-VEGF Agents Explanation: ***Prevention of venous thrombosis and pulmonary embolism***
- Anticoagulants are highly effective in inhibiting the formation and extension of **venous thrombi**, thereby directly preventing **deep vein thrombosis (DVT)** and **pulmonary embolism (PE)**.
- The mechanism of action targets the **coagulation cascade**, directly reducing the risk of these venous thromboembolic events, which are a major indication for anticoagulant therapy.
*Prevention of recurrences of myocardial infarction*
- While anticoagulants may play a secondary role, **antiplatelet agents** (e.g., aspirin, clopidogrel) are the primary therapy for preventing recurrent myocardial infarction, as **arterial thrombi** are predominantly platelet-rich.
- Anticoagulants are used in specific high-risk situations post-MI (e.g., **atrial fibrillation**, left ventricular thrombus) but are not generally considered the primary preventive strategy.
*Cerebrovascular accident*
- The benefit of anticoagulants for stroke prevention is primarily significant in cases of **cardioembolic stroke** (e.g., due to **atrial fibrillation**) where they prevent clot formation in the heart.
- For non-cardioembolic **ischemic strokes** (e.g., thrombotic or lacunar), antiplatelet agents are generally preferred for secondary prevention.
*Retinal artery thrombosis*
- **Retinal artery thrombosis** is often caused by **arterial atherosclerosis** and **embolism** from the carotid arteries or heart, where antiplatelet agents are typically primary.
- The role of anticoagulants here is limited to specific causes like **atrial fibrillation** or in patients already on anticoagulation for other indications.
Anti-VEGF Agents Indian Medical PG Question 10: Treatment of choice for clinically significant macular edema in a diabetic is?
- A. Intravitreal anti-VEGF injections (Correct Answer)
- B. Control of Diabetes
- C. Panretinal Photocoagulation
- D. Focal Photocoagulation
Anti-VEGF Agents Explanation: ***Intravitreal anti-VEGF injections***
- **Anti-VEGF agents** (e.g., ranibizumab, aflibercept) are the first-line treatment for **clinically significant diabetic macular edema (DME)** as they effectively reduce vascular leakage and improve vision.
- They target **vascular endothelial growth factor (VEGF)**, a key mediator of increased vascular permeability and neovascularization in diabetic retinopathy.
*Control of Diabetes*
- While essential for preventing the **progression of diabetic retinopathy** and overall health, it is not the primary direct treatment for *existing* clinically significant macular edema.
- Good glycemic control can reduce the *risk* of developing DME but does not acutely resolve established edema.
*Panretinal Photocoagulation*
- **Panretinal photocoagulation (PRP)** is primarily used for **proliferative diabetic retinopathy (PDR)** to ablate ischemic retina and reduce neovascularization.
- It is not the treatment of choice for macular edema, as it can sometimes worsen macular function and visual acuity due to treatment-induced damage.
*Focal Photocoagulation*
- **Focal laser photocoagulation** was historically used for DME, targeting discrete leaking microaneurysms.
- While effective for specific focal leakage, it has largely been superseded by **anti-VEGF injections** due to their superior efficacy in diffuse edema and better visual outcomes, especially when edema involves the fovea.
More Anti-VEGF Agents Indian Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
